Clinical Trials | December 24, 2025
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
Adverse events were consistent with valbenazine’s established safety profile
Adverse events were consistent with valbenazine’s established safety profile
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
Subscribe To Our Newsletter & Stay Updated
